JANX - Janux Therapeutics Has Positive Catalysts And Could Get Cheaper
2023-05-09 04:02:31 ET
Summary
- Despite the recent rebound, US-listed biotech stocks valuations are still "down to earth" compared to the strong recovery from the Covid-19 crisis.
- Relatively low market valuations offer an opportunity to add to positions in biotechnology stocks with promising prospects.
- Janux Therapeutics is an interesting stock as this US developer of Tumor Activated T Cell Engager [TRACTr] and Tumor Activated Immunomodulator [TRACIr] immunotherapies has some catalysts for higher stock prices.
- Janux Therapeutics, Inc. stock deserves a Hold rating rather than a Buy rating now because it could get cheaper.
For further details see:
Janux Therapeutics Has Positive Catalysts And Could Get Cheaper